Navigation Links
Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
Date:8/2/2011

ommercialize JX-594 in South Korea, and Lee's Pharmaceutical Ltd. holds an exclusive license to develop and commercialize JX-594 in China.

Transgene, a member of the Institut Merieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases, and has five compounds in clinical development: TG4010 and JX-594 (TG6006) having completed initial phase II trials, TG4001 in phase IIb trial, TG4040 in phase II trial and TG4023 in phase I trial. Transgene has concluded strategic agreements for the development of two of its immunotherapy products, an option agreement with Novartis for the development of TG4010 to treat various cancers, and an in-licensing agreement with U.S.-based Jennerex Biotherapeutics, Inc., to develop and market JX-594 (TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available on the internet at www.transgene.fr

Green Cross Corp. is a publicly traded and leading Korean biopharmaceutical company specialized in development and commercialization of vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies in oncology and infectious diseases. Green Cross Corp. has been collaborating with Jennerex in Korea since 2006 to jointly conduct the Phase 1 and 2 clinical trials in patients with liver cancer. Additional information about Green Cross Corp. is available on the internet at www.greencross.com.

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 16 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives a
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
3. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
4. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
5. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
6. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
9. Jennerex Closes $5 Million First Tranche of Series C Financing
10. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
11. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
(Date:7/29/2015)... - BioAmber Inc. (NYSE: BIOA ) today announced that ... has resigned.  The Company has hired Andrew Ashworth ... December 2014, as full time interim CFO and has ... Andy Ashworth began his employment today, to ... Andy was the Company,s CFO from September 2011 to ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... U.S. Secretary of Health and Human Services Tommy Thompson has ... , a provider of information systems for high-acuity care areas ... room and the intensive care unit. , ,Thompson began his ... Wisconsin's state Assembly. He was elected assistant Assembly minority leader ...
... has approved a $500,000 start-up grant for the ... group for classified, defense-related projects. , ,The ... also initially include the UW System, the Medical ... and the Milwaukee School of Engineering. , ,The ...
... National LambdaRail Two UW-Madison computer science professors, ... have been named to the National LambdaRails Networking Researching ... the high-speed fiber optic networks research goals. , ,The ... educational groups across the country, which over the past ...
Cached Biology Technology:Wisconsin consortium aims for defense business 2Two UW-Madison professors named to National LambdaRail Networking Research Council 2
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... the nature of crowds playing Foldit called some strategies ... methods already used by protein scientists., Gamers made headlines ... central to research on AIDS. Today, in a ... National Academy of Sciences, University of Washington researchers ...
... 2011 AVT, Inc. (formerly Automated Vending Technologies) (Ticker: ... provide a new line of Secure Automated Retailing Systems ... This new system provides extra security for automated ... customer is critical. AVT worked with ...
... characterize the genes involved in wood formation in poplar trees ... wood as a feedstock for biofuels production. "This ... work of other biofuels researchers who develop better and more ... Beers, professor of horticulture and the lead investigator on the ...
Cached Biology News:Paper uncovers power of Foldit gamers' strategies 2Paper uncovers power of Foldit gamers' strategies 3AVT Partners with MedBox to Provide New Biometric Fingerprint Recognition for Secure Automated Retailing 2Genomics of wood for biofuels production investigated 2
... enables complete conversion of unmethylated cytosines ... hours. The highly sensitive method utilizes ... and a spin-column-based purification and desulfonation ... results for all downstream applications. The ...
... Shimadzus GCMS-QP2010s Gas Chromatograph/Mass Spectrometer, ... of the GCMS-QP2010 Plus, offers high ... with an excellent performance-to-cost ratio. Like ... patented constant linear velocity for optimum ...
... enterprise microarray informatics platform for microarray data storage, ... and use it forever without paying ongoing license ... Acuity has all the analysis tools you need ... quality control statistics and normalization, all the way ...
... Pro is the industry standard microarray image ... of imaging and analysis tools, visualizations, automation ... Pro is included with every GenePix scanner, ... third-party scanners and all types of arrays. ...
Biology Products: